Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia

Journal of Clinical Pharmacology

Volumn 43, Issue 6, 2003, Pages 565-572

  Galanello, Renzo ^b   Piga, Antonio ^b   Alberti, Daniele ^b   Rouan, Marie Claude ^b   Bigler, Hilde ^b   Séchaud, Romain ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NONE

Author keywords

ICL670; Iron overload; Oral chelation; Pharmacokinetics; Safety

Indexed keywords

4 [3,5 BIS(HYDROXYPHENYL) 1,2,4 TRIAZOL 1 YL]BENZOIC ACID; DEFERASIROX; IRON CHELATING AGENT; IRON COMPLEX; PLACEBO; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; HEADACHE; HUMAN; IRON CHELATION; IRON OVERLOAD; MALE; MULTICENTER STUDY; NAUSEA; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL;

EID: 0037906104     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003253350     Document Type: Article

References (7)

1. Weatherall DJ, Clegg JB: The Thalassemia Syndromes. 4th ed. Oxford, UK: Blackwell Scientific, 2001.
2. Cohen AR: Management of iron overload in the pediatric patient, in: Oski FA (ed.), Pediatric Hematology: Hematology/Oncology Clinics of North America. Philadelphia: W. B. Saunders, 1987;521.
3. Sephton-Smith R: Iron excretion in thalassemia major after administration of chelating agents. Brit Med J 1962;2:1577-1580.
4. Olivieri NF, Brittenham GM: Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-761.
5. Barman Balfour JA, Foster RH: Deferriprone: a review of its clinical potential in iron overload in beta-thalassemia and other transfusion-dependent diseases. Drugs 1999;58:553-578.
6. Nick HP, Wong A, Acklin P, Faller B, Jin Y, Lattmann R, et al: ICL670A: Preclinical profile [book chapter]. New York: Kluwer/ Plenum, in press.
7. Rouan MC, Marfil F, Mangoni P, Séchaud R, Humbert H, Maurer G: Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection. J Chromatogr 2001;755:203-213.